tiprankstipranks
Trending News
More News >

Tiziana Life Sciences announces UMass commences Phase 2 na-SPMS trial

Tiziana Life Sciences (TLSA) announced that dosing has commenced at the fourth clinical site in its ongoing Phase 2 trial evaluating intranasal foralumab in patients with non-active secondary progressive multiple sclerosi, na-SPMS. The University of Massachusetts, UMass, has now joined Brigham and Women’s Hospital, Yale Multiple Sclerosis Center, and Johns Hopkins University Autoimmunity Center of Excellence in actively dosing participants.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue